Myopic choroidal neovascularization(m CNV), one of the complications of pathological myopia, is also one of the leading causes of visual impairment worldwide. The socioeconomic impact of mC NV in Asian countries is pa...Myopic choroidal neovascularization(m CNV), one of the complications of pathological myopia, is also one of the leading causes of visual impairment worldwide. The socioeconomic impact of mC NV in Asian countries is particularly significant due to the rising incidence of pathological myopia. There have been major advances in the treatment of mC NV in the past few years. Previous treatment modalities, such as thermal laser photocoagulation and photodynamic therapy, aimed to prevent vision loss;however, newer modalities such as intravitreal anti-vascular endothelial growth factor(VEGF) agents have been shown to successfully restore vision in many patients. Challenges remain as long term safety and efficacy of anti-VEGF agents are unknown. This article aims to provide a review of the literature of the epidemiology, progression, clinical course and treatment modalities as well as areas of future developments related to myopic CNV.展开更多
AIM:To observe the long-term clinical efficacy of intravitreal injections of conbercept,a novel vascular growth factor inhibitor,for the treatment of pathological myopia choroidal neovascularization(PM-CNV).METHODS:A ...AIM:To observe the long-term clinical efficacy of intravitreal injections of conbercept,a novel vascular growth factor inhibitor,for the treatment of pathological myopia choroidal neovascularization(PM-CNV).METHODS:A total of 67 eyes(from 67 patients;mean age,54.90±12.7y)with PM-CNV were retrospectively researched.Based on the different schemes used for the administration of the drug,the patients were divided into two groups:group A(n=35;average age,53.31±13.6y;average diopter,9.25±1.72 D),which received only one injection of pro re nata(PRN;1+PRN regimen),and group B(n=32;average age,56.49±11.8y;average diopter,9.63±2.24 D),which received one injection per month for 3mo(3+PRN regimen).Best-corrected visual acuity(BCVA)analysis,intraocular pressure(IOP)examination,slit-lamp microscopy,fundus examination and optical coherence tomography were per formed at each follow-up.The recurrence and treatment times of CNV were recorded.The patients were followed up for at least 12mo.RESULTS:The BCVA was increased in 29 eyes(82.9%)in group A and 30 eyes(93.75%)in group B;no increase or decrease was observed in 6(17.1%)and 2(6.25%)eyes in groups A and B,respectively.The BCVA(log MAR)values before treatment(0.67±0.48 and 0.71±0.56)were significantly higher than those 12mo after treatment(0.31±0.26 and 0.33±0.17)in groups A and B,respectively(P<0.05).The mean central macular thickness(CMT)values had significantly decreased from 346.49±65.99 and 360.10±82.31μm at baseline to 257.29±40.47 and 251.97±48.26μm in groups A and B,respectively,after 12mo of treatment.A total of 21 eyes in group A needed reinjection(60%;average number of injections,2.51±0.98);the corresponding values in group B were 6 eyes(18.75%;average number of injections,3.74±1.22).There were no adverse ocular and systemic complications during the treatment and follow-up.CONCLUSION:Intravitreal injection of conbercept with 1+PRN or 3+PRN improve the visual acuity,reduce macular edema and reduce the level of CMT in patients with PM-CNV.The 3+PRN regimen demonstrates a lower recurrence rate of CNV than the 1+PRN regimen,but requires more treatment.However,both treatment regimens demonstrate long-term safety and efficacy for the treatment of PM-CNV.展开更多
AIM: To evaluate the visual outcomes of choroidal neovascularization (CNV) secondary to pathological myopia and the impact of novel risk factors affecting the final visual outcome. ·METHODS: Interventional case s...AIM: To evaluate the visual outcomes of choroidal neovascularization (CNV) secondary to pathological myopia and the impact of novel risk factors affecting the final visual outcome. ·METHODS: Interventional case series of 18 consecutive patients with pathological myopia treated with photodynamic therapy (PDT). Inclusion criteria were spherical equivalent -6D or worse or features of pathological myopia on retinal examination. The main outcome measure was final best -corrected visual acuity (BCVA). ·RESULTS: Of 18 eyes, 13 (72.2%) avoided moderate visual loss (≥3 lines of LogMAR BCVA) and 5 eyes (27.8%) improved by at least 1 line after 1 year. Patients with LogMAR BCVA ≤0.3 (Snellen equivalent 20/40) at one year were younger than those with BCVA 】0.3 (mean age 39.0 vs 61.6 years, P =0.001). A higher proportion of eyes with greatest linear dimension (GLD) of ≤1 000μm avoided moderate visual loss (100% vs 50%, P =0.026). Among patients who were treated within 2 weeks of visual symptoms, 88.9% avoided the loss of 3 or more lines compared to 55.6% for those who presented later. The mean improvement in LogMAR BCVA of those with GLD ≤1 000μm was +0.12 compared to a loss of 0.55 LogMAR units for those with GLD 】1 000μm (P =0.02). Visual outcomes were not associated with gender or refractive error.·CONCLUSION: Good visual outcome in myopic CNV is associated with younger age, smaller lesion size and earlier initiation of treatment. These factors are relevant for ophthalmologists considering treatment options for myopic CNV.展开更多
Choroidal neovascularization(CNV)is an uncommon complication associated with a macular hole.In this case report of a rare condition,we present a pathologic myopia patient with a co-existent macular hole and choroidal ...Choroidal neovascularization(CNV)is an uncommon complication associated with a macular hole.In this case report of a rare condition,we present a pathologic myopia patient with a co-existent macular hole and choroidal neovascular membrane.The patient was treated with photodynamic therapy for CNV,and then vitreous surgery for the retinal detachment and macular hole.At the end of 4 years follow-up,her visual acuity was improved to 0.1 while the macular hole remained open.Optical coherence tomography is a useful inspection method of the diagnosis of CNV and macular hole.展开更多
AIM:To evaluate the clinical application value of the artificial intelligence assisted pathologic myopia(PM-AI)diagnosis model based on deep learning.METHODS:A total of 1156 readable color fundus photographs were coll...AIM:To evaluate the clinical application value of the artificial intelligence assisted pathologic myopia(PM-AI)diagnosis model based on deep learning.METHODS:A total of 1156 readable color fundus photographs were collected and annotated based on the diagnostic criteria of Meta-pathologic myopia(PM)(2015).The PM-AI system and four eye doctors(retinal specialists 1 and 2,and ophthalmologists 1 and 2)independently evaluated the color fundus photographs to determine whether they were indicative of PM or not and the presence of myopic choroidal neovascularization(mCNV).The performance of identification for PM and mCNV by the PMAI system and the eye doctors was compared and evaluated via the relevant statistical analysis.RESULTS:For PM identification,the sensitivity of the PM-AI system was 98.17%,which was comparable to specialist 1(P=0.307),but was higher than specialist 2 and ophthalmologists 1 and 2(P<0.001).The specificity of the PM-AI system was 93.06%,which was lower than specialists 1 and 2,but was higher than ophthalmologists 1 and 2.The PM-AI system showed the Kappa value of 0.904,while the Kappa values of specialists 1,2 and ophthalmologists 1,2 were 0.968,0.916,0.772 and 0.730,respectively.For mCNV identification,the AI system showed the sensitivity of 84.06%,which was comparable to specialists 1,2 and ophthalmologist 2(P>0.05),and was higher than ophthalmologist 1.The specificity of the PM-AI system was 95.31%,which was lower than specialists 1 and 2,but higher than ophthalmologists 1 and 2.The PM-AI system gave the Kappa value of 0.624,while the Kappa values of specialists 1,2 and ophthalmologists 1 and 2 were 0.864,0.732,0.304 and 0.238,respectively.CONCLUSION:In comparison to the senior ophthalmologists,the PM-AI system based on deep learning exhibits excellent performance in PM and mCNV identification.The effectiveness of PM-AI system is an auxiliary diagnosis tool for clinical screening of PM and mCNV.展开更多
-yopia is the most common refractive disorder. High .myopia affects 27%-33% of all myopic eyes inAsia.1,2 ;The pathologic myopia （PM） is the most severe vision-threatening phenotype of high myopia.3 It is also the s...-yopia is the most common refractive disorder. High .myopia affects 27%-33% of all myopic eyes inAsia.1,2 ;The pathologic myopia （PM） is the most severe vision-threatening phenotype of high myopia.3 It is also the second most common cause of choroidal neovascularization （CNV） in Asia. Unlike age-related macular degeneration （AMD） which mostly effecting elders, PM causes severe vision loss in young adults, resulting in a significant impairment of their working ability.4 PM has become the second leading cause of low vision and blindness particularly among those aged at 40-49 years in some Asia countries.展开更多
文摘Myopic choroidal neovascularization(m CNV), one of the complications of pathological myopia, is also one of the leading causes of visual impairment worldwide. The socioeconomic impact of mC NV in Asian countries is particularly significant due to the rising incidence of pathological myopia. There have been major advances in the treatment of mC NV in the past few years. Previous treatment modalities, such as thermal laser photocoagulation and photodynamic therapy, aimed to prevent vision loss;however, newer modalities such as intravitreal anti-vascular endothelial growth factor(VEGF) agents have been shown to successfully restore vision in many patients. Challenges remain as long term safety and efficacy of anti-VEGF agents are unknown. This article aims to provide a review of the literature of the epidemiology, progression, clinical course and treatment modalities as well as areas of future developments related to myopic CNV.
文摘AIM:To observe the long-term clinical efficacy of intravitreal injections of conbercept,a novel vascular growth factor inhibitor,for the treatment of pathological myopia choroidal neovascularization(PM-CNV).METHODS:A total of 67 eyes(from 67 patients;mean age,54.90±12.7y)with PM-CNV were retrospectively researched.Based on the different schemes used for the administration of the drug,the patients were divided into two groups:group A(n=35;average age,53.31±13.6y;average diopter,9.25±1.72 D),which received only one injection of pro re nata(PRN;1+PRN regimen),and group B(n=32;average age,56.49±11.8y;average diopter,9.63±2.24 D),which received one injection per month for 3mo(3+PRN regimen).Best-corrected visual acuity(BCVA)analysis,intraocular pressure(IOP)examination,slit-lamp microscopy,fundus examination and optical coherence tomography were per formed at each follow-up.The recurrence and treatment times of CNV were recorded.The patients were followed up for at least 12mo.RESULTS:The BCVA was increased in 29 eyes(82.9%)in group A and 30 eyes(93.75%)in group B;no increase or decrease was observed in 6(17.1%)and 2(6.25%)eyes in groups A and B,respectively.The BCVA(log MAR)values before treatment(0.67±0.48 and 0.71±0.56)were significantly higher than those 12mo after treatment(0.31±0.26 and 0.33±0.17)in groups A and B,respectively(P<0.05).The mean central macular thickness(CMT)values had significantly decreased from 346.49±65.99 and 360.10±82.31μm at baseline to 257.29±40.47 and 251.97±48.26μm in groups A and B,respectively,after 12mo of treatment.A total of 21 eyes in group A needed reinjection(60%;average number of injections,2.51±0.98);the corresponding values in group B were 6 eyes(18.75%;average number of injections,3.74±1.22).There were no adverse ocular and systemic complications during the treatment and follow-up.CONCLUSION:Intravitreal injection of conbercept with 1+PRN or 3+PRN improve the visual acuity,reduce macular edema and reduce the level of CMT in patients with PM-CNV.The 3+PRN regimen demonstrates a lower recurrence rate of CNV than the 1+PRN regimen,but requires more treatment.However,both treatment regimens demonstrate long-term safety and efficacy for the treatment of PM-CNV.
基金Dr. Tan receives travel support from BayerBayer. Dr. Lim receives travel support from Novartis, Bayer and Heidelberg Engineering
文摘AIM: To evaluate the visual outcomes of choroidal neovascularization (CNV) secondary to pathological myopia and the impact of novel risk factors affecting the final visual outcome. ·METHODS: Interventional case series of 18 consecutive patients with pathological myopia treated with photodynamic therapy (PDT). Inclusion criteria were spherical equivalent -6D or worse or features of pathological myopia on retinal examination. The main outcome measure was final best -corrected visual acuity (BCVA). ·RESULTS: Of 18 eyes, 13 (72.2%) avoided moderate visual loss (≥3 lines of LogMAR BCVA) and 5 eyes (27.8%) improved by at least 1 line after 1 year. Patients with LogMAR BCVA ≤0.3 (Snellen equivalent 20/40) at one year were younger than those with BCVA 】0.3 (mean age 39.0 vs 61.6 years, P =0.001). A higher proportion of eyes with greatest linear dimension (GLD) of ≤1 000μm avoided moderate visual loss (100% vs 50%, P =0.026). Among patients who were treated within 2 weeks of visual symptoms, 88.9% avoided the loss of 3 or more lines compared to 55.6% for those who presented later. The mean improvement in LogMAR BCVA of those with GLD ≤1 000μm was +0.12 compared to a loss of 0.55 LogMAR units for those with GLD 】1 000μm (P =0.02). Visual outcomes were not associated with gender or refractive error.·CONCLUSION: Good visual outcome in myopic CNV is associated with younger age, smaller lesion size and earlier initiation of treatment. These factors are relevant for ophthalmologists considering treatment options for myopic CNV.
基金Public Welfare Technology Project of Science Technology Department of Zhejiang Province,China(No.2012C23068)
文摘Choroidal neovascularization(CNV)is an uncommon complication associated with a macular hole.In this case report of a rare condition,we present a pathologic myopia patient with a co-existent macular hole and choroidal neovascular membrane.The patient was treated with photodynamic therapy for CNV,and then vitreous surgery for the retinal detachment and macular hole.At the end of 4 years follow-up,her visual acuity was improved to 0.1 while the macular hole remained open.Optical coherence tomography is a useful inspection method of the diagnosis of CNV and macular hole.
文摘AIM:To evaluate the clinical application value of the artificial intelligence assisted pathologic myopia(PM-AI)diagnosis model based on deep learning.METHODS:A total of 1156 readable color fundus photographs were collected and annotated based on the diagnostic criteria of Meta-pathologic myopia(PM)(2015).The PM-AI system and four eye doctors(retinal specialists 1 and 2,and ophthalmologists 1 and 2)independently evaluated the color fundus photographs to determine whether they were indicative of PM or not and the presence of myopic choroidal neovascularization(mCNV).The performance of identification for PM and mCNV by the PMAI system and the eye doctors was compared and evaluated via the relevant statistical analysis.RESULTS:For PM identification,the sensitivity of the PM-AI system was 98.17%,which was comparable to specialist 1(P=0.307),but was higher than specialist 2 and ophthalmologists 1 and 2(P<0.001).The specificity of the PM-AI system was 93.06%,which was lower than specialists 1 and 2,but was higher than ophthalmologists 1 and 2.The PM-AI system showed the Kappa value of 0.904,while the Kappa values of specialists 1,2 and ophthalmologists 1,2 were 0.968,0.916,0.772 and 0.730,respectively.For mCNV identification,the AI system showed the sensitivity of 84.06%,which was comparable to specialists 1,2 and ophthalmologist 2(P>0.05),and was higher than ophthalmologist 1.The specificity of the PM-AI system was 95.31%,which was lower than specialists 1 and 2,but higher than ophthalmologists 1 and 2.The PM-AI system gave the Kappa value of 0.624,while the Kappa values of specialists 1,2 and ophthalmologists 1 and 2 were 0.864,0.732,0.304 and 0.238,respectively.CONCLUSION:In comparison to the senior ophthalmologists,the PM-AI system based on deep learning exhibits excellent performance in PM and mCNV identification.The effectiveness of PM-AI system is an auxiliary diagnosis tool for clinical screening of PM and mCNV.
基金This study was supported by grants from the China National Basic Research Program （973 Program, No. 2011CB707506）, China National Natural Science Foundation （No. 81271030 and No. 81100678）, Shanghai Key Basic Research Grant （No. 11JC141601）, Shanghai Scholar Leadship Grant （No. 12XD1404100）, and Shanghai Committee of Science and Technology Guide Grant （No. 114119a7000）.
文摘-yopia is the most common refractive disorder. High .myopia affects 27%-33% of all myopic eyes inAsia.1,2 ;The pathologic myopia （PM） is the most severe vision-threatening phenotype of high myopia.3 It is also the second most common cause of choroidal neovascularization （CNV） in Asia. Unlike age-related macular degeneration （AMD） which mostly effecting elders, PM causes severe vision loss in young adults, resulting in a significant impairment of their working ability.4 PM has become the second leading cause of low vision and blindness particularly among those aged at 40-49 years in some Asia countries.
